Physician profile
Chia-Wei Lin
NPI 1508491549
$14,817.68
in general payments reported to CMS, 2019-2025
23 companies · $3,840 in 2025
The $3,840 reported for 2025 was more than what 99% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,838 · 2022: $1,748 · 2023: $3,522 · 2024: $2,870 · 2025: $3,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,039.33 |
| Education | $192.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,124.87 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $2,183.15 | 2021-2025 | Ingrezza |
| Abbvie INC. | $1,500.23 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,230.08 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $970.70 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $954.56 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $943.52 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $760.01 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $500.23 | 2021-2023 | |
| Corium, LLC | $476.20 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $416.59 | 2022-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $278.67 | 2024-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $261.39 | 2022 | |
| Janssen Pharmaceuticals, INC | $221.96 | 2022-2023 | Invega Sustenna, Invega Trinza |
| Allergan, INC. | $214.08 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $198.21 | 2021-2024 | |
| Almatica Pharma LLC | $179.67 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Neos Therapeutics, Lp | $121.46 | 2023-2024 | Adzenys Xr-Odt |
| Boston Scientific Corporation | $117.62 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Supernus Pharmaceuticals, INC. | $76.33 | 2022 | |
| Tris Pharma INC | $58.33 | 2024-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $16.75 | 2023 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $13.07 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chia-Wei Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.